Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P19525
UPID:
E2AK2_HUMAN
Alternative names:
Eukaryotic translation initiation factor 2-alpha kinase 2; Interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein kinase; Protein kinase RNA-activated; Tyrosine-protein kinase EIF2AK2; p68 kinase
Alternative UPACC:
P19525; A8K3P0; D6W584; E9PC80; Q52M43; Q7Z6F6; Q9UIR4
Background:
Interferon-induced, double-stranded RNA-activated protein kinase, also known as EIF2AK2, plays a pivotal role in the innate immune response to viral infection. It phosphorylates EIF2S1/eIF-2-alpha, leading to a shutdown of protein synthesis, which is crucial for combating viral replication. Additionally, EIF2AK2 is involved in various cellular processes including apoptosis, cell proliferation, and differentiation.
Therapeutic significance:
EIF2AK2's involvement in Leukoencephalopathy and Dystonia 33 highlights its potential as a therapeutic target. Understanding the role of EIF2AK2 could open doors to potential therapeutic strategies for these neurological disorders, offering hope for advancements in treatment.